| __timestamp | AstraZeneca PLC | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 20707000 |
| Thursday, January 1, 2015 | 5997000000 | 17831000 |
| Friday, January 1, 2016 | 5890000000 | 18047000 |
| Sunday, January 1, 2017 | 5757000000 | 11033000 |
| Monday, January 1, 2018 | 5932000000 | 13432000 |
| Tuesday, January 1, 2019 | 5958000000 | 52072000 |
| Wednesday, January 1, 2020 | 5991000000 | 51488000 |
| Friday, January 1, 2021 | 9736000000 | 85727000 |
| Saturday, January 1, 2022 | 9762000000 | 95518000 |
| Sunday, January 1, 2023 | 10935000000 | 125046000 |
| Monday, January 1, 2024 | 13583000000 |
Igniting the spark of knowledge
In the ever-evolving landscape of pharmaceutical research, AstraZeneca PLC and Geron Corporation stand as intriguing contrasts. From 2014 to 2023, AstraZeneca's investment in research and development (R&D) has surged by nearly 96%, peaking at over $10 billion in 2023. This reflects AstraZeneca's commitment to innovation, particularly in oncology and cardiovascular therapies. Meanwhile, Geron Corporation, a smaller player, has seen its R&D expenses grow by over 500% during the same period, reaching approximately $125 million in 2023. This growth underscores Geron's focus on pioneering treatments in the field of telomerase inhibition. While AstraZeneca's R&D spending dwarfs that of Geron, the latter's strategic investments highlight its potential to disrupt niche markets. This juxtaposition of scale and specialization offers a fascinating glimpse into the diverse strategies driving pharmaceutical advancements today.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and AstraZeneca PLC
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and HUTCHMED (China) Limited
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: Intra-Cellular Therapies, Inc. and Geron Corporation
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Geron Corporation
Research and Development Expenses Breakdown: Amneal Pharmaceuticals, Inc. vs Geron Corporation
Research and Development Investment: Soleno Therapeutics, Inc. vs Geron Corporation
Comparing Innovation Spending: Geron Corporation and Viridian Therapeutics, Inc.